SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 5.19 |
| Enterprise Value ($M) | 5.30 |
| Book Value ($M) | -7.76 |
| Book Value / Share | -1.19 |
| Price / Book | -0.67 |
| NCAV ($M) | -9.21 |
| NCAV / Share | -1.41 |
| Price / NCAV | -0.56 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -3.47 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.04 |
| Current Ratio | 0.04 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.39 |
| Assets | 1.83 |
| Liabilities | 9.60 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -11.69 |
| Net Income | -11.62 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -9.09 |
| Cash from Investing | 0.01 |
| Cash from Financing | 7.97 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 4.99 | -96.29 | |
| 13G | Ruck Matthew J | 5.18 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 22,316 | 47,565 | 46.92 | |
| 23,548 | 106,547 | 22.10 | |
| 22,479 | 64,083 | 35.08 | |
| 3,731 | 39,247 | 9.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AVTX – Avalo Therapeutics, Inc. | AYTU – Aytu BioPharma, Inc. |
| BCDA – BioCardia, Inc. | BCTX – BriaCell Therapeutics Corp. |
| BFRG – Bullfrog AI Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io